Dr. Manuel Davila , MD
Dermatology • Pasadena, TX
4419 Crenshaw Rd
Pasadena, TX 775043628
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on November 29, 2005; this date does not establish years in practice.
-
Published CMS data list 5,248 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- 17003 — Destruction of precancer skin growth, 2-14 growths: 2,224 service units.
- 99213 — Established patient outpatient office visit: 845 service units.
- 17110 — Destruction of skin growth, 1-14 growths: 698 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 15 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 2,700 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Triamcinolone Acetonide — 306 prescription fills, including refills.
- Mupirocin — 252 prescription fills, including refills.
- Ciclopirox (Ciclopirox Olamine) — 244 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 35 records in the table · Guide: How to read Medicare Part D prescriber data
-
More Medicare Part B services than 75% of clinicians listed under Dermatology in Texas (2024, 827 clinicians with data). Median for this group: 2,195. Middle half: 1,085 to 4,742.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 4,499 in 2020 to 5,248 in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020–2024.
Practice Location & Contact Primary Location
4419 Crenshaw Rd
Pasadena, TX 775043628
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
CMS Doctors and Clinicians lists 1 group name: Southeast Dermatology, P.A.. See the list
Source: CMS Doctors and Clinicians National Downloadable File, release date unavailable.
Listings do not confirm current availability, employment or a shared ownership network.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File
University Of Iowa, Rj & L Carver College Of Medicine
2000
What Public CMS Data Show
Dermatology: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
514 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.
Medicare-allowed amount
About $293,771 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
Paid by Medicare
About $216,652 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
30-day fills
3,521 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$863,312 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $5,550.09 across 276 records.
By nature of payment
- Food and Beverage: $5,451.09 across 275 records.
- Education: $99.00 across 1 record.
Reporting-company totals (3 largest of 24)
- ABBVIE INC.: $684.46 across 37 records.
- Novartis Pharmaceuticals Corporation: $476.78 across 23 records.
- LEO Pharma Inc.: $455.87 across 27 records.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
26 years (graduated 2000)
CMS Doctors and Clinicians data list 2000 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File.
NPI first issued
2005
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Dr. Davila has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Davila as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Pasadena and Texas
Billing and prescribing volume is not a quality rating.
Medicare Part B services
More Medicare Part B services than 75% of clinicians listed under Dermatology in Texas (2024, 827 clinicians with data). Median for this group: 2,195. Middle half: 1,085 to 4,742.
Too few clinicians listed under Dermatology in Pasadena have Medicare Part B data for 2024 to compare.
Medicare-allowed amount
A higher Medicare-allowed amount than 75% of clinicians listed under Dermatology in Texas (2024, 827 clinicians with data). Median for this group: $135,212. Middle half: $65,517 to $291,099.
Too few clinicians listed under Dermatology in Pasadena have Medicare Part B data for 2024 to compare.
Paid by Medicare
A higher Medicare payment amount than 75% of clinicians listed under Dermatology in Texas (2024, 827 clinicians with data). Median for this group: $95,715. Middle half: $45,692 to $209,369.
Too few clinicians listed under Dermatology in Pasadena have Medicare Part B data for 2024 to compare.
Medicare Part D prescriptions
More Part D prescriptions than 95% of clinicians listed under Dermatology in Texas (2024, 922 clinicians with data). Median for this group: 486. Middle half: 202 to 949.
Too few clinicians listed under Dermatology in Pasadena have Medicare Part D data for 2024 to compare.
Part D drug cost
A higher Part D drug cost than 95% of clinicians listed under Dermatology in Texas (2024, 922 clinicians with data). Median for this group: $81,547. Middle half: $6,986 to $226,319.
Too few clinicians listed under Dermatology in Pasadena have Medicare Part D data for 2024 to compare.
11 active clinicians are listed under Dermatology with a practice address in Pasadena, TX (1,173 in Texas).
Addresses are self-reported to NPPES and may be out of date.
Telehealth indicator in Pasadena
0% of these 11 clinicians have the CMS telehealth indicator.
90.9% of these 11 clinicians are listed by CMS as accepting Medicare assignment.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services increased 17% from 4,499 in 2020 to 5,248 in 2024.
- 2020: 4,499
- 2021: 4,453
- 2022: 4,738
- 2023: 4,964
- 2024: 5,248
-
Medicare-allowed amount
Medicare-allowed amount increased 29% from $227,719 in 2020 to $293,771 in 2024.
- 2020: $227,719
- 2021: $234,397
- 2022: $259,418
- 2023: $283,592
- 2024: $293,771
-
Paid by Medicare
Paid by Medicare increased 33% from $162,616 in 2020 to $216,652 in 2024.
- 2020: $162,616
- 2021: $168,164
- 2022: $188,553
- 2023: $207,960
- 2024: $216,652
-
Medicare Part D prescriptions
Medicare Part D prescriptions increased 20% from 2,250 in 2020 to 2,700 in 2024.
- 2020: 2,250
- 2021: 2,172
- 2022: 2,121
- 2023: 2,217
- 2024: 2,700
-
30-day fills
30-day fills increased 35% from 2,602 in 2020 to 3,521 in 2024.
- 2020: 2,602
- 2021: 2,628
- 2022: 2,609
- 2023: 2,823
- 2024: 3,521
-
Part D drug cost
Part D drug cost increased 50% from $573,990 in 2020 to $863,312 in 2024.
- 2020: $573,990
- 2021: $546,583
- 2022: $619,398
- 2023: $740,362
- 2024: $863,312
-
Industry payments (Open Payments)
Industry payments (Open Payments) increased 51% from $3,676.67 in 2021 to $5,550.09 in 2025.
- 2021: $3,676.67
- 2022: $5,602.87
- 2023: $6,538.68
- 2024: $6,554.00
- 2025: $5,550.09
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 276 records totaling $5,550.09.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| MERZ NORTH AMERICA, INC. |
Food and Beverage
In-kind items and services
|
Xeomin | General | $133.96 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
ILUMYA | General | $124.98 |
| Incyte Corporation |
Food and Beverage
Cash or cash equivalent
|
Opzelura | General | $124.97 |
| Journey Medical Corporation |
Food and Beverage
In-kind items and services
|
— | General | $123.68 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $122.88 |
| Arcutis Biotherapeutics, Inc. |
Food and Beverage
In-kind items and services
|
Zoryve | General | $103.65 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
Odomzo | General | $99.10 |
| Janssen Pharmaceuticals, Inc |
Education
In-kind items and services
|
TREMFYA | General | $99.00 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
Winlevi | General | $98.07 |
| Eli Lilly and Company |
Food and Beverage
In-kind items and services
|
EBGLYSS | General | $93.19 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $86.55 |
| Journey Medical Corporation |
Food and Beverage
In-kind items and services
|
— | General | $55.00 |
| Amgen Inc. |
Food and Beverage
In-kind items and services
|
OTEZLA | General | $49.50 |
| UCB, Inc. |
Food and Beverage
In-kind items and services
|
Bimzelx | General | $45.78 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $40.44 |
| UCB, Inc. |
Food and Beverage
In-kind items and services
|
Bimzelx | General | $40.19 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
ILUMYA | General | $35.52 |
| UCB, Inc. |
Food and Beverage
In-kind items and services
|
Bimzelx | General | $35.16 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $34.37 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $33.80 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $33.58 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
ILUMYA | General | $32.72 |
| Regeneron Pharmaceuticals, Inc. |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $32.17 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
— | General | $31.76 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $31.53 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
17003
Destruction of precancer skin growth, 2-14 growths
|
2,224 | 251 | $25.00 | $6.87 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
845 | 445 | $152.00 | $95.83 |
|
17110
Destruction of skin growth, 1-14 growths
|
698 | 391 | $191.00 | $114.62 |
|
17000
Destruction of precancer skin growth, 1 growth
|
534 | 317 | $111.00 | $38.66 |
|
11102
Biopsy of related skin growth, first growth
|
395 | 282 | $175.00 | $61.97 |
|
17004
Destruction of precancer skin growth, 15 or more growths
|
167 | 95 | $278.00 | $176.03 |
|
11103
Biopsy of related skin growth, each additional growth
|
97 | 74 | $89.00 | $52.83 |
|
17111
Destruction of skin growth, 15 or more growths
|
67 | 45 | $224.00 | $134.46 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
63 | 48 | $215.00 | $135.48 |
|
99203
New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
|
41 | 41 | $186.00 | $115.21 |
|
12032
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm
|
32 | 29 | $519.00 | $319.12 |
|
J3301
Injection, triamcinolone acetonide, not otherwise specified, 10 mg
|
27 | 12 | $5.19 | $1.00 |
|
10060
Simple or single drainage of skin abscess
|
26 | 23 | $207.00 | $134.51 |
|
99212
Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
|
17 | 15 | $93.00 | $59.58 |
|
69100
Biopsy of ear
|
15 | 15 | $167.00 | $56.70 |
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Triamcinolone Acetonide | Triamcinolone Acetonide | 306 | 9,429 | $3,147.84 | 219 |
| Mupirocin | Mupirocin | 252 | 4,566 | $1,652.05 | 170 |
| Ciclopirox | Ciclopirox Olamine | 244 | 7,889 | $6,702.05 | 120 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 194 | 5,299 | $3,762.39 | 108 |
| Clobetasol Propionate | Clobetasol Propionate | 188 | 5,359 | $9,422.41 | 118 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 151 | 12,792 | $1,851.99 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 3,677 | $3,589.69 | 89 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 113 | 7,882 | $1,536.89 | 55 |
| Terbinafine Hcl | Terbinafine Hcl | 103 | 3,014 | $972.12 | 42 |
| Clindamycin Phosphate | Clindamycin Phosphate | 102 | 3,000 | $3,845.45 | 56 |
| Fluocinonide | Fluocinonide | 91 | 2,831 | $4,970.62 | 56 |
| Minoxidil | Minoxidil | 84 | 7,054 | $847.79 | 33 |
| Ketoconazole | Ketoconazole | 74 | 2,040 | $932.53 | 33 |
| Taltz Autoinjector | Ixekizumab | 61 | 1,708 | $420,128.28 | — |
| Fluorouracil | Fluorouracil | 55 | 1,666 | $4,222.29 | 50 |
| Ciclopirox | Ciclopirox | 53 | 1,465 | $1,366.54 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 1,535 | $427.70 | 12 |
| Minocycline Hcl | Minocycline Hcl | 43 | 1,474 | $801.91 | — |
| Otezla | Apremilast | 41 | 1,226 | $199,517.68 | — |
| Valacyclovir | Valacyclovir Hcl | 35 | 641 | $364.55 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 969 | $470.01 | 15 |
| Metronidazole | Metronidazole | 33 | 921 | $1,709.55 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 1,018 | $782.44 | 17 |
| Mometasone Furoate | Mometasone Furoate | 29 | 820 | $543.75 | 13 |
| Cephalexin | Cephalexin | 24 | 206 | $125.89 | 18 |
(top 25 shown)
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
Self-certified to NPPES: 2022-07-19NUCC Taxonomy Code: 207N00000X
A dermatologist is trained to diagnose and treat pediatric and adult patients with benign and malignant disorders of the skin, mouth, external genitalia, hair and nails, as well as a number of sexually transmitted diseases. The dermatologist has had additional training and experience in the diagnosis and treatment of skin cancers, melanomas, moles and other tumors of the skin, the management of contact dermatitis and other allergic and nonallergic skin disorders, and in the recognition of the skin manifestations of systemic (including internal malignancy) and infectious diseases. Dermatologists have special training in dermatopathology and in the surgical techniques used in dermatology. They also have expertise in the management of cosmetic disorders of the skin such as hair loss and scars and the skin changes associated with aging.
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - DERMATOLOGY
I20040805001617
TX
9739150210
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Medicare Group Practice Enrollments
Source: CMS Doctors and Clinicians National Downloadable File
Southeast Dermatology, P.a.
4419 Crenshaw Rd, Pasadena, TX 775043628
Phone: 2819915944
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Dermatology
Doctor of Medicine (M.D.)
Dermatology
Doctor of Medicine (M.D.)
Dermatology
Doctor of Medicine (M.D.)
Dermatology
Doctor of Medicine (M.D.)
Dermatology
Doctor of Medicine (M.D.)
Dermatology
Doctor of Medicine (M.D.)
Career & Practice History
NPI enumerated November 29, 2005.
No changes to the name, practice address, taxonomy or NPI status in this record have been observed in the monthly NPPES data files from January 2017 to August 2026.
NPI Administrative Meta
Other Dermatology Specialists in Pasadena
- Dr. Whitney Latin, MD
- Dr. Paula Leis, MD
- Dr. Christine Hunt, MD
- Dr. Isha Lopez, MD
- Dr. Mary Garman, MD
- Dr. Elizabeth Schepp, MD
Mailing Address
4419 Crenshaw Rd
Pasadena, TX 775043628
Phone: 2819915944